Reata Pharmaceuticals (Reata Pharmaceuticals) Debt-to-Equity : 1.90 (As of Jun. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Reata Pharmaceuticals Debt-to-Equity?

Reata Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $2.46 Mil. Reata Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $163.55 Mil. Reata Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $87.29 Mil. Reata Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2023 was 1.90.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Reata Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

RETA' s Debt-to-Equity Range Over the Past 10 Years
Min: -17.26 Med: -0.09 Max: 31.16
Current: 1.9

During the past 10 years, the highest Debt-to-Equity Ratio of Reata Pharmaceuticals was 31.16. The lowest was -17.26. And the median was -0.09.

RETA's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs RETA: 1.90

Reata Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Reata Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reata Pharmaceuticals Debt-to-Equity Chart

Reata Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

5.23

0.60

0.01

0.73

-1.82

Reata Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-Equity	Get a 7-Day Free Trial															2.08	31.16	-1.82	-0.90	1.90

Competitive Comparison of Reata Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Reata Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Reata Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reata Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Reata Pharmaceuticals's Debt-to-Equity falls into.

Reata Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Reata Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.151	+	117.313)	/	-65.695
	=	-1.82

Reata Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.456	+	163.547)	/	87.291
	=	1.90

Reata Pharmaceuticals (NAS:RETA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Reata Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Reata Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Reata Pharmaceuticals (Reata Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reata Pharmaceuticals Inc (NAS:RETA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

5320 Legacy Drive, Plano, TX, USA, 75024

Website

https://www.reatapharma.com

Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.

Executives

Steven Ryder	director	234 CHURCH STREET, SUITE 1020, NEW HAVEN CT 06510
Antal Rohit Desai	director, 10 percent owner	C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Rajiv Patni	officer: EVP, Chief R&D Officer	C/O OCERA THERAPEUTICS, INC., 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Bhaskar Anand	officer: SVP, Chief Accounting Officer	5320 LEGACY DRIVE, PLANO TX 75024
Manmeet Singh Soni	officer: COO, CFO and President	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Martin Edwards	director	15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Dawn Carter Bir	officer: Chief Commercial Officer	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DRIVE, SUITE 150, IRVING TX 75063
Christy J. Oliger	director	85 WELLS AVENUE, SUITE 210, NEWTON MA 02459
Andrea Loewen	officer: SVP, Global Regulatory Affairs	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Shamim Ruff	director	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Mcclellan William D. Jr.	director	C/O APOLLO ENDOSURGERY, INC., 1120 S., CAPITAL OF TEXAS HWY, BLDG. 1, SUITE 300, AUSTIN TX 78746
Michael D Wortley	officer: See Remarks	5320 LEGACY DRIVE, PLANO TX 75024
Meyer Colin John	officer: See Remarks	C/O REATA PHARMACEUTICALS, INC., 2801 GATEWAY DR. SUITE 150, IRVING TX 75063
Biogen Inc.	other: See footnotes	225 BINNEY STREET, CAMBRIDGE MA 02142
Samina Khan	officer: SVP, Chief Medical Officer	5320 LEGACY DRIVE, PLANO TX 75024